

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Prostate cancer	Aldo-keto reductase family 1 member C3 (AKR1C3)	<i>In vitro</i> studies identified specific AKR1C3 inhibitors that could help treat castration-resistant prostate cancer. AKR1C3 is upregulated in castration-resistant prostate cancer. In <i>in vitro</i> assays, flufenamic acid-based compounds selectively inhibited AKR1C3 with nanomolar potencies. In a prostate cancer cell line overexpressing AKR1C3, the lead inhibitor decreased testosterone formation compared with no treatment. Next steps include testing the inhibitors in xenograft models of castration-resistant prostate cancer.	Patent applications filed; disclosed and other undisclosed compounds available for licensing	Adeniji, A.O. <i>et al.</i> <i>J. Med. Chem.</i> ; published online Jan. 20, 2012; doi:10.1021/jm201547v <b>Contact:</b> Trevor M. Penning, University of Pennsylvania, Philadelphia, Pa. e-mail: <a href="mailto:penning@upenn.edu">penning@upenn.edu</a> <b>Contact:</b> Jeffrey D. Winkler, same affiliation as above e-mail: <a href="mailto:winkler@sas.upenn.edu">winkler@sas.upenn.edu</a>
		<b>SciBX 5(6); doi:10.1038/scibx.2012.152</b> Published online Feb. 9, 2012		